Cargando…
CpG Oligodeoxynucleotide Developed to Activate Primate Immune Responses Promotes Antitumoral Effects in Combination with a Neoantigen-Based mRNA Cancer Vaccine
PURPOSE: The purpose of our research was to identify and evaluate synthetic phosphorothioate-modified CPG oligodeoxynucleotides (CPG-ODNs) activating innate and adaptive immune responses. Furthermore, combined treatment with CpG and an mRNA cancer vaccine was evaluated in melanoma models as a therap...
Autores principales: | Li, Qin, Ren, Jie, Liu, Wei, Jiang, Guoqin, Hu, Rongkuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459178/ https://www.ncbi.nlm.nih.gov/pubmed/34566407 http://dx.doi.org/10.2147/DDDT.S325790 |
Ejemplares similares
-
CpG oligodeoxynucleotides as mucosal adjuvants
por: Iho, Sumiko, et al.
Publicado: (2015) -
CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody
por: Hiramatsu, Kosuke, et al.
Publicado: (2015) -
Systemic Administration of CpG Oligodeoxynucleotide and Levamisole as Adjuvants for Gene-Gun-Delivered Antitumor DNA Vaccines
por: Šmahel, Michal, et al.
Publicado: (2011) -
Type II natural killer T cells foster the antitumor activity of CpG-oligodeoxynucleotides
por: Zhao, Jie, et al.
Publicado: (2014) -
A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice
por: Yu, Pengcheng, et al.
Publicado: (2018)